Betahistine

Phase 2Small molecule

OOBEcure Ltd.

Betahistine is one of 7 small molecule programs targeting Dizziness. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DizzinessUnknown status

VertigoRecruiting

DizzinessPreclinical

Unknown status

VertigoPhase 2

Recruiting

Competition

Competitive Landscape

7 competitors in Vertigo

#DrugCompanyPhaseTrials

Reglan

IIstituto Clinico Humanitas

Approved

1 2

Valium

Akero Therapeutics

Approved

—3

Dimenhydrinate

SSt. Justine's Hospital

Phase 3

2 4

Zofran

Novartis

Preclinical

1 5

Betahistine

OOBEcure Ltd.

Phase 2

1 6

Trental

VValidus Pharmaceuticals

Preclinical

1 7

Benadryl

PParkedale

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Drug Interactions1 trial

Evaluation of Safety, Drug-Drug Interactions and Pharmacokinetic Profiles of Co-Administration of Betahistine With Olanzapine in Healthy Female Subjects

Completed·OOBEcure Ltd.·Phase 1·NCT00852956·50 enrolled

Dizziness1 trial

Interventions for Residual Dizziness After Successful Repositioning Maneuvers in Patients With BPPV

Unknown status·EEye & ENT Hospital of Fudan University·N/A·NCT03624283·183 enrolled

Vertigo1 trial

Modulating Auditory Symptoms and Vertigo of Meniere's Disease by Non-invasive Mastoid Electric Stimulation

Recruiting·SSeoul National University Hospital·Phase 1/2·NCT06001593·120 enrolled

Double-blind1 trial

A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effect of Betahistine on Plasma Lipids in Patients Treated With Simvastatin

Terminated·OOBEcure Ltd.·Phase 2·NCT00466869·30 enrolled

Body Weight Gain1 trial

Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment

Terminated·OOBEcure Ltd.·Phase 2·NCT00428168·36 enrolled

3 more indications

Body Weight1 trial

The Effect of Betahistine on Body Weight in Obese Subjects

Completed·OOBEcure Ltd.·Phase 2·NCT00409305·280 enrolled

Olanzapine1 trial

Evaluation of Co-Administration of Betahistine as Adjunctive to Olanzapine in Healthy Subjects

Completed·OOBEcure Ltd.·Phase 1·NCT01168336·90 enrolled

Weight Gain1 trial

Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain

Completed·NNathan Kline Institute for Psychiatric Research·Phase 2·NCT00709202·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Betahistine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Betahistine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Betahistine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — OBEcure Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOBEcure Ltd.

Betahistine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Drug Interactions1 trial

Dizziness1 trial

Vertigo1 trial

Double-blind1 trial

Body Weight Gain1 trial

Body Weight1 trial

Olanzapine1 trial

Weight Gain1 trial

References

Drug Info

Quick Facts

Related News